1 |
Hofherr, S. E., Mok, H., Gushiken, F. C., Lopez, J. A. and Barry, M. A. (2007) Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum. Gene Ther. 18, 837-848.
DOI
ScienceOn
|
2 |
Ogawara, K., Rots, M. G., Kok, R. J., Moorlag, H. E., Van Loenen, A. M., Meijer, D. K., Haisma, H. J. and Molema, G. (2004) A nsovel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum. Gene Ther. 15, 433-443.
DOI
ScienceOn
|
3 |
Park, J. W., Mok, H. and Park, T. G. (2008) Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus. Biochem. Biophys. Res. Commun. 366, 769-774.
DOI
ScienceOn
|
4 |
Bonsted, A., Engesaeter, B. O., Hogset, A., Maelandsmo, G. M., Prasmickaite, L., D'Oliveira, C., Hennink, W. E., van Steenis, J. H. and Berg, K. (2006) Photochemically enhanced transduction of polymer-complexed adenovirus targeted to the epidermal growth factor receptor. J. Gene Med. 8, 286-297.
DOI
ScienceOn
|
5 |
Morrison, J., Briggs, S. S., Green, N., Fisher, K., Subr, V., Ulbrich, K., Kehoe, S. and Seymour, L. W. (2008) Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. Mol. Ther. 16, 244-251.
DOI
ScienceOn
|
6 |
Maeda, M., Kida, S., Hojo, K., Eto, Y., Gaob, J. Q., Kurachi, S., Sekiguchi, F., Mizuguchi, H., Hayakawa, T., Mayumi, T., Nakagawa, S. and Kawasaki, K. (2005) Design and synthesis of a peptide-PEG transporter tool for carrying adenovirus vector into cells. Bioorg. Med. Chem. Lett. 15, 621-624.
DOI
ScienceOn
|
7 |
Oh, I. K., Mok, H. and Park, T. G. (2006) Folate immobilized and PEGylated adenovirus for retargeting to tumor cells. Bioconjug. Chem. 17, 721-727.
DOI
ScienceOn
|
8 |
Eto, Y., Gao, J. Q., Sekiguchi, F., Kurachi, S., Katayama, K., Maeda, M., Kawasaki, K., Mizuguchi, H., Hayakawa, T., Tsutsumi, Y., Mayumi, T. and Nakagawa, S. (2005) PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J. Gene Med. 7, 604-612.
DOI
ScienceOn
|
9 |
Gao, J. Q., Eto, Y., Yoshioka, Y., Sekiguchi, F., Kurachi, S., Morishige, T., Yao, X., Watanabe, H., Asavatanabodee, R., Sakurai, F., Mizuguchi, H., Okada, Y., Mukai, Y., Tsutsumi, Y., Mayumi, T., Okada, N. and Nakagawa, S. (2007) Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. J. Control Release 122, 102-110.
DOI
ScienceOn
|
10 |
Gressner, A. M. and Pfeiffer, T. (1986) Preventive effects of acute inflammation on liver cell necrosis and inhibition of heparan sulphate synthesis in hepatocytes. J. Clin. Chem. Clin. Biochem. 24, 821-829.
|
11 |
Shayakhmetov, D. M., Li, Z. Y., Ni, S. and Lieber, A. (2004) Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J. Virol. 78, 5368-5381.
DOI
|
12 |
Barton, K. N., Stricker, H., Kolozsvary, A., Kohl, R., Heisey, G., Nagaraja, T. N., Zhu, G., Lu, M., Kim, J. H., Freytag, S. O. and Brown, S. L. (2006) Polyethylene glycol (molecular weight 400 DA) vehicle improves gene expression of adenovirus mediated gene therapy. J. Urol. 175, 1921-1925.
DOI
ScienceOn
|
13 |
Fisher, K. D., Stallwood, Y., Green, N. K., Ulbrich, K., Mautner, V. and Seymour, L. W. (2001) Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 8, 341-348.
DOI
|
14 |
Green, N. K., Morrison, J., Hale, S., Briggs, S. S., Stevenson, M., Subr, V., Ulbrich, K., Chandler, L., Mautner, V., Seymour, L. W. and Fisher, K. D. (2008) Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. J. Gene Med. 10, 280-289.
DOI
ScienceOn
|
15 |
Hofherr, S. E., Shashkova, E. V., Weaver, E. A., Khare, R. and Barry, M. A. (2008) Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol. Ther. 16, 1276-1282.
DOI
ScienceOn
|
16 |
Pearce, O. M., Fisher, K. D., Humphries, J., Seymour, L. W., Smith, A. and Davis, B. G. (2005) Glycoviruses: chemical glycosylation retargets adenoviral gene transfer. Angew. Chem. Int. Ed. Engl. 44, 1057-1061.
DOI
ScienceOn
|
17 |
Lee, G. K., Maheshri, N., Kaspar, B. and Schaffer, D. V. (2005) PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization. Biotechnol. Bioeng. 92, 24-34.
DOI
ScienceOn
|
18 |
Jung, Y., Park, H. J., Kim, P. H., Lee, J., Hyung, W., Yang, J., Ko, H., Sohn, J. H., Kim, J. H., Huh, Y. M., Yun, C. O. and Haam, S. (2007) Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells. J. Control Release 123, 164-171.
DOI
ScienceOn
|
19 |
Yao, X., Yoshioka, Y., Morishige, T., Eto, Y., Watanabe, H., Okada, Y., Mizuguchi, H., Mukai, Y., Okada, N. and Nakagawa, S. (2009) Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis. Gene Ther. 16, 1395-1404.
DOI
ScienceOn
|
20 |
Chan, P., Kurisawa, M., Chung, J. E. and Yang, Y. Y. (2007) Synthesis and characterization of chitosan-g-poly(ethylene glycol)-folate as a non-viral carrier for tumor-targeted gene delivery. Biomaterials 28, 540-549.
DOI
ScienceOn
|
21 |
Doronin, K., Shashkova, E. V., May, S. M., Hofherr, S. E. and Barry, M. A. (2009) Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum. Gene Ther. 20, 975-988.
DOI
ScienceOn
|
22 |
Kiang, A., Hartman, Z. C., Everett, R. S., Serra, D., Jiang, H., Frank, M. M. and Amalfitano, A. (2006) Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system. Mol. Ther. 14, 588-598.
DOI
ScienceOn
|
23 |
Zhang, Y. A., Nemunaitis, J., Samuel, S. K., Chen, P., Shen, Y. and Tong, A. W. (2006) Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Cancer Res. 66, 9736-9743.
DOI
ScienceOn
|
24 |
Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., Randlev, B., Gillenwater, A. M., Bruso, P., Kaye, S. B., Hong, W. K. and Kirn, D. H. (2000) A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879-885.
DOI
ScienceOn
|
25 |
Nemunaitis, J., Ganly, I., Khuri, F., Arseneau, J., Kuhn, J., McCarty, T., Landers, S., Maples, P., Romel, L., Randlev, B., Reid, T., Kaye, S. and Kirn, D. (2000) Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 60, 6359-6366.
|
26 |
Singh, R. and Kostarelos, K. (2009) Designer adenoviruses for nanomedicine and nanodiagnostics. Trends. Biotechnol. 27, 220-229.
DOI
ScienceOn
|
27 |
Li, F., Zhang, Z. P., Peng, J., Cui, Z. Q., Pang, D. W., Li, K., Wei, H. P., Zhou, Y. F., Wen, J. K. and Zhang, X. E. (2009) Imaging viral behavior in Mammalian cells with self-assembled capsid-quantum-dot hybrid particles. Small 5, 718-726.
DOI
ScienceOn
|
28 |
Thompson, D. H. (2008) Adenovirus in a synthetic membrane wrapper: an example of hybrid vigor? ACS Nano 2, 821-826.
DOI
ScienceOn
|
29 |
Fisher, K. D. and Seymour, L. W. (2010) HPMA copolymers for masking and retargeting of therapeutic viruses. Adv. Drug. Deliv. Rev. 62, 240-245.
DOI
ScienceOn
|
30 |
Yoo, J. Y., Kim, J. H., Kim, J., Huang, J. H., Zhang, S. N., Kang, Y. A., Kim, H. and Yun, C. O. (2008) Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. Gene Ther. 15, 635-651.
DOI
ScienceOn
|
31 |
Zhao, L., Dong, A., Gu, J., Liu, Z., Zhang, Y., Zhang, W., Wang, Y., He, L., Qian, C., Qian, Q. and Liu, X. (2006) The anti-tumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther. 13, 1011-1022.
DOI
ScienceOn
|
32 |
Steinwaerder, D. S., Carlson, C. A., Otto, D. L., Li, Z. Y., Ni, S. and Lieber, A. (2001) Tumor-specific gene expression in hepatic metastases by a replication-activated adenovirus vector. Nat. Med. 7, 240-243.
DOI
ScienceOn
|
33 |
Chengalvala, M. V., Lubeck, M. D., Selling, B. J., Natuk, R. J., Hsu, K. H., Mason, B. B., Chanda, P. K., Bhat, R. A., Bhat, B. M., Mizutani, S. (1991) Adenovirus vectors for gene expression. Curr. Opin. Biotechnol. 2, 718-722.
DOI
ScienceOn
|
34 |
Alemany, R., Balague, C. and Curiel, D. T. (2000) Replicative adenoviruses for cancer therapy. Nat. Biotechnol. 18, 723-727.
DOI
ScienceOn
|
35 |
Green, N. K., Herbert, C. W., Hale, S. J., Hale, A. B., Mautner, V., Harkins, R., Hermiston, T., Ulbrich, K., Fisher, K. D. and Seymour, L. W. (2004) Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther. 11, 1256-1263.
DOI
ScienceOn
|
36 |
Choi, I. K., Lee, Y. S., Yoo, J. Y., Yoon, A. R., Kim, H., Kim, D. S., Seidler, D. G., Kim, J. H. and Yun, C. O. (2010) Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy. Gene Ther. 17, 190-201.
DOI
ScienceOn
|
37 |
Gomes, E. M., Rodrigues, M. S., Phadke, A. P., Butcher, L. D., Starling, C., Chen, S., Chang, D., Hernandez-Alcoceba, R., Newman, J. T., Stone, M. J. and Tong, A. W. (2009) Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clin. Cancer Res. 15, 1317-1325.
DOI
ScienceOn
|
38 |
Chen, L., Chen, D., Gong, M., Na, M., Li, L., Wu, H., Jiang, L., Qian, Y., Fang, G. and Xue, X. (2009) Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells. Cancer Lett. 284, 141-148.
DOI
ScienceOn
|
39 |
Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L. and Kirn, D. (2000) An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6, 1134-1139.
DOI
ScienceOn
|
40 |
Kim, J. H., Lee, Y. S., Kim, H., Huang, J. H., Yoon, A. R. and Yun, C. O. (2006) Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J. Natl. Cancer Inst. 98, 1482-1493.
DOI
ScienceOn
|
41 |
Kim, P. H., Kim, T. I., Yockman, J. W., Kim, S. W. and Yun, C. O. (2010) The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy. Biomaterials 31, 1865-1874.
DOI
ScienceOn
|
42 |
Park, Y., Kang, E., Kwon, O. J., Hwang, T., Park, H., Lee, J. M., Kim, J. H. and Yun, C. O. (2010) Ionically crosslinked Ad/chitosan nanocomplexes processed by electro-spinning for targeted cancer gene therapy. J. Control Release. S0168-3659(10)00475-X [pii] 10.1016/j.jconrel.2010.06.027.
DOI
ScienceOn
|
43 |
Mok, H., Park, J. W. and Park, T. G. (2008) Enhanced intracellular delivery of quantum dot and adenovirus nanoparticles triggered by acidic pH via surface charge reversal. Bioconjug. Chem. 19, 797-801.
DOI
ScienceOn
|
44 |
Park, J. W., Mok, H. and Park, T. G. (2010) Physical adsorption of PEG grafted and blocked poly-L-lysine copolymers on adenovirus surface for enhanced gene transduction. J. Control Release 142, 238-244.
DOI
ScienceOn
|
45 |
Sarkar, D., Lebedeva, I. V., Su, Z. Z., Park, E. S., Chatman, L., Vozhilla, N., Dent, P., Curiel, D. T. and Fisher, P. B. (2007) Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res. 67, 5434-5442.
DOI
ScienceOn
|
46 |
Sarkar, D., Su, Z. Z. and Fisher, P. B. (2006) Unique conditionally replication competent bipartite adenoviruses-cancer terminator viruses (CTV): efficacious reagents for cancer gene therapy. Cell Cycle. 5, 1531-1536.
DOI
|
47 |
Cattaneo, R., Miest, T., Shashkova, E. V. and Barry, M. A. (2008) Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat. Rev. Microbiol. 6, 529-540.
DOI
ScienceOn
|
48 |
Saini, V., Martyshkin, D. V., Mirov, S. B., Perez, A., Perkins, G., Ellisman, M. H., Towner, V. D., Wu, H., Pereboeva, L., Borovjagin, A., Curiel, D. T. and Everts, M. (2008) An adenoviral platform for selective self-assembly and targeted delivery of nanoparticles. Small 4, 262-269.
DOI
ScienceOn
|
49 |
Lanciotti, J., Song, A., Doukas, J., Sosnowski, B., Pierce, G., Gregory, R., Wadsworth, S. and O'Riordan, C. (2003) Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Mol. Ther. 8, 99-107.
DOI
ScienceOn
|